Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Small Cell Lung Carcinoma 19Breast Neoplasms 16Sarcoma 12Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 7Carcinoma, Hepatocellular 7Thyroid Neoplasms 6Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Esophageal Neoplasms 6Ovarian Neoplasms 5NSCLC 5Carcinoma 5Triple Negative Breast Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Neoplasms 3Glioma 3Cholangiocarcinoma 3Brain Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Platinum-resistant Ovarian Cancer 2

Interventions

venetoclax 1pyrotinib 1pertuzumab 1penpulimab 1palbociclib 1dalpiciclib 1anlotinib 1Tretinoin 1Trastuzumab 1Ropivacaine 1Radiosurgery 1Propofol 1Patient Reported Outcome Measures 1Paclitaxel 1Ondansetron 1Morphine 1Letrozole 1Induction Chemotherapy 1Fulvestrant 1Etoricoxib 1Docetaxel 1Diagnostic Imaging 1Carboplatin 1Capecitabine 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasm Female × anlotinib × Clear all
NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡